nnc0385-0434
Small moleculeexperimental
Clinical trial activity
7 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
6
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Aug 20, 2019 (NCT04058834)
Timeline
Indications
Mechanism of action
- Subtilisin/kexin type 9INHIBITOR
PCSK9 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05333107 | Phase 1 | Apr 12, 2022 | Novo Nordisk |
| NCT05091073 | Phase 1 | Nov 29, 2021 | Novo Nordisk |
| NCT05094934 | Phase 1 | Nov 9, 2021 | Novo Nordisk |
| NCT05129891 | Phase 1 | Nov 3, 2021 | Novo Nordisk |
| NCT05003440 | Phase 1 | Aug 19, 2021 | Novo Nordisk |
| NCT04992065 | Phase 2 | Aug 3, 2021 | Novo Nordisk |
| NCT04058834 | Phase 1 | Aug 20, 2019 | Novo Nordisk |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Novo Nordisk | For profit | 7 | 7 | 2 | 2019 |
1 organizations
Page 1 / 1